5 658

Cited 36 times in

A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.

DC Field Value Language
dc.contributor.author김세규-
dc.contributor.author김주항-
dc.contributor.author박무석-
dc.contributor.author손주혁-
dc.contributor.author심효섭-
dc.contributor.author양우익-
dc.contributor.author이익재-
dc.contributor.author이주희-
dc.contributor.author이창걸-
dc.contributor.author최혜진-
dc.contributor.author권지은-
dc.date.accessioned2014-12-20T16:26:26Z-
dc.date.available2014-12-20T16:26:26Z-
dc.date.issued2011-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/92720-
dc.description.abstractPURPOSE: This study was undertaken to determine safety and tolerability of nimotuzumab, a humanized anti-epidermal growth factor receptor monoclonal antibody, in combination with radiotherapy in stages IIB-IV non-small cell lung cancer (NSCLC) patients who are unsuitable for radical therapy or chemotherapy. METHODS: Nimotuzumab (100mg, 200mg and 400mg) was administered weekly from week 1 to week 8 with palliative radiotherapy (30-36 Gy, 3 Gy/day). If tumor control was achieved, nimotuzumab was continued every 2 weeks until unacceptable toxicity or disease progression. Serial skin biopsies were collected for pharmacodynamic assessment. RESULTS: Fifteen patients were enrolled in the study, with cohorts of five patients assigned in each dose level of nimotuzumab. Patients and disease characteristics included median age 73 years; Eastern Cooperative Oncology Group performance status (PS) 0-1/2 (n=3/12); female sex (n=2); adenocarcinoma (n=5); never-smoker status (n=2); and stages IIB/IIIB/IV (n=1/8/6). All patients were unable to tolerate radical therapy because of old age or multiple comorbidities. The most commonly reported adverse events were lymphopenia and asthenia (grades 1-2 in most patients). No skin rash or allergic toxicities appeared. Dose-limiting toxicity occurred with pneumonia with grade 4 neutropenia at the 200mg dose of nimotuzumab. Objective response rate and disease control rate inside the radiation field were 46.7% and 100.0%, respectively. CONCLUSIONS: Nimotuzumab in combination with radiotherapy is well-tolerated and feasible. Further clinical investigation of nimotuzumab in NSCLC patients is warranted.-
dc.description.statementOfResponsibilityopen-
dc.format.extent55~59-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntibodies, Monoclonal/administration & dosage*-
dc.subject.MESHAntibodies, Monoclonal/adverse effects*-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/adverse effects-
dc.subject.MESHCarcinoma,Non-Small-CellLung/drugtherapy*-
dc.subject.MESHCarcinoma,Non-Small-CellLung/radiotherapy*-
dc.subject.MESHCombined ModalityTherapy-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLungNeoplasms/drugtherapy*-
dc.subject.MESHLungNeoplasms/radiotherapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPhosphorylation/drug effects-
dc.subject.MESHReceptor, Epidermal Growth Factor/antagonists & inhibitors-
dc.subject.MESHReceptor, Epidermal Growth Factor/metabolism-
dc.subject.MESHRepublic of Korea-
dc.titleA phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHye Jin Choi-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorChang Geol Lee-
dc.contributor.googleauthorHyo Sub Shim-
dc.contributor.googleauthorIk-Jae Lee-
dc.contributor.googleauthorWoo Ick Yang-
dc.contributor.googleauthorJi Eun Kwon-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorMoo-Suk Park-
dc.contributor.googleauthorJu Hee Lee-
dc.contributor.googleauthorJoo Hang Kim-
dc.identifier.doi10.1016/j.lungcan.2010.04.010-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00602-
dc.contributor.localIdA00945-
dc.contributor.localIdA01457-
dc.contributor.localIdA01995-
dc.contributor.localIdA02219-
dc.contributor.localIdA02300-
dc.contributor.localIdA03055-
dc.contributor.localIdA03240-
dc.contributor.localIdA04219-
dc.contributor.localIdA00253-
dc.contributor.localIdA03171-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid20451284-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500210001698-
dc.subject.keywordNimotuzumab-
dc.subject.keywordPhase I-
dc.subject.keywordEpidermal growth factor receptor (EGFR) inhibitor-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordPalliative radiotherapy-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNamePark, Moo Suk-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.alternativeNameYang, Woo Ick-
dc.contributor.alternativeNameLee, Ik Jae-
dc.contributor.alternativeNameLee, Ju Hee-
dc.contributor.alternativeNameLee, Chang Geol-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.alternativeNameKwon, Ji Eun-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorPark, Moo Suk-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorShim, Hyo Sup-
dc.contributor.affiliatedAuthorYang, Woo Ick-
dc.contributor.affiliatedAuthorLee, Ik Jae-
dc.contributor.affiliatedAuthorLee, Chang Geol-
dc.contributor.affiliatedAuthorChoi, Hye Jin-
dc.contributor.affiliatedAuthorKwon, Ji Eun-
dc.contributor.affiliatedAuthorLee, Ju Hee-
dc.rights.accessRightsnot free-
dc.citation.volume71-
dc.citation.number1-
dc.citation.startPage55-
dc.citation.endPage59-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.71(1) : 55-59, 2011-
dc.identifier.rimsid28718-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.